GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.
about
Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan BiosynthesisADME of biologics-what have we learned from small molecules?Revisiting the role of glycosylation in the structure of human IgG Fc.Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.Nanoengineered glycan sensors enabling native glycoprofiling for medicinal applications: towards profiling glycoproteins without labeling or liberation steps.Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.Marketing approval of mogamulizumab: a triumph for glyco-engineering.Biosimilar, biobetter and next generation therapeutic antibodies6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry.Inactivation of a GAL4-like transcription factor improves cell fitness and product yield in glycoengineered Pichia pastoris strains.One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates.Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.
P2860
Q27673777-622B7702-291C-4F07-94F4-AB2E22F34B90Q36065589-A2D7071F-6EC5-47F4-83F9-EE9D3244D3E6Q36252642-048D8DBD-897E-4FB5-9B65-B3C340E0698FQ37547107-2B41D6EE-BC17-4092-BFDE-7D868FEBAB65Q38032457-2676C5B7-4C0C-4E6D-B09E-E4D7BD5718F2Q39025466-CA891EBE-AA83-41C2-AE57-A0CCA01C6124Q41177029-B4CD4BAF-B3F8-43C9-87C6-8DF7A39BD051Q41718653-8D8960E2-0430-4A6A-9BC6-9F2F91C8DD43Q42333453-A08E55E6-C64E-4BA8-897D-01117225B330Q42732007-73CF37E2-A4CE-47DB-AFA1-4402767ADAB1Q42732008-F83C45B9-B2E7-4EF1-8B87-DFE0EC323D81Q42869354-3DF8E294-8CF9-4E50-B7AA-76C8FCADD83EQ42906654-03D1FBDF-57AF-4751-8197-E5A6D8B98767Q43074457-1D5C2643-0A0E-49B2-B3F2-336000C1DEA5Q48987144-3B1E9A5E-EF80-4576-8612-57355DDD897CQ50133462-CE29D219-AD03-4CA3-9C2E-F9388C297A19Q51238255-F83216BC-02EE-49EF-950D-060A07A7A567
P2860
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.
@en
type
label
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.
@en
prefLabel
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.
@en
P2093
P2860
P1476
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.
@en
P2093
Alain Beck
Olivier Cochet
Thierry Wurch
P2860
P304
P356
10.1517/17460440903413504
P407
P577
2009-12-01T00:00:00Z